Page last updated: 2024-09-03

gefitinib and celecoxib

gefitinib has been researched along with celecoxib in 31 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(celecoxib)
Trials
(celecoxib)
Recent Studies (post-2010) (celecoxib)
5,2315662,9195,2738432,428

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)celecoxib (IC50)
Chain A, Carbonic anhydrase IIHomo sapiens (human)0.021
Prostaglandin E synthaseHomo sapiens (human)0.4825
Histone deacetylase 3Homo sapiens (human)1.637
Prostaglandin G/H synthase 1 Bos taurus (cattle)7.9667
Prostaglandin G/H synthase 2 Bos taurus (cattle)0.057
Cytochrome c oxidase subunit 1Ovis aries (sheep)6.5
Cytochrome c oxidase subunit 2Ovis aries (sheep)0.0881
Catechol O-methyltransferaseMus musculus (house mouse)0.036
Cytochrome c oxidase subunit 2Homo sapiens (human)0.371
Carbonic anhydrase 1Homo sapiens (human)0.1555
Carbonic anhydrase 2Homo sapiens (human)0.0925
Prostaglandin G/H synthase 1Ovis aries (sheep)5.271
Procathepsin LHomo sapiens (human)0.56
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)7.308
Seed linoleate 13S-lipoxygenase-1Glycine max (soybean)0.07
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)4.295
Cytochrome P450 2D6Homo sapiens (human)1
Cytochrome P450 2C9 Homo sapiens (human)10
Calpain-2 catalytic subunitHomo sapiens (human)0.002
Alpha-2B adrenergic receptorHomo sapiens (human)1.516
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)0.12
Prostaglandin G/H synthase 1Mus musculus (house mouse)3.6401
Prostaglandin G/H synthase 1Homo sapiens (human)3.5499
Sodium-dependent noradrenaline transporter Homo sapiens (human)7.308
Indoleamine 2,3-dioxygenase 1Mus musculus (house mouse)0.006
Sodium-dependent serotonin transporterHomo sapiens (human)6.276
Prostaglandin G/H synthase 2Homo sapiens (human)0.3818
Prostaglandin G/H synthase 2 Rattus norvegicus (Norway rat)0.4028
Urotensin-2 receptorRattus norvegicus (Norway rat)7.6
Histone deacetylase 4Homo sapiens (human)1.637
D(2) dopamine receptorRattus norvegicus (Norway rat)0.03
Prostaglandin G/H synthase 2Ovis aries (sheep)0.6343
Mu-type opioid receptorCavia porcellus (domestic guinea pig)7.7
Sodium-dependent dopamine transporter Homo sapiens (human)2.431
Prostaglandin G/H synthase 2Mus musculus (house mouse)0.045
Histone deacetylase 1Homo sapiens (human)1.411
Mitogen-activated protein kinase 14Homo sapiens (human)0.81
Carbonic anhydrase 9Homo sapiens (human)0.016
Sigma intracellular receptor 2Rattus norvegicus (Norway rat)0.05
Prostaglandin G/H synthase 1 Rattus norvegicus (Norway rat)0.3
Prostaglandin G/H synthase 1Canis lupus familiaris (dog)5.57
Cyclooxygenase-2 Canis lupus familiaris (dog)0.9
Histone deacetylase 7Homo sapiens (human)1.637
Histone deacetylase 2Homo sapiens (human)1.637
Carbonic anhydrase 4Bos taurus (cattle)0.2227
Polyamine deacetylase HDAC10Homo sapiens (human)1.637
Histone deacetylase 11 Homo sapiens (human)1.637
Histone deacetylase 8Homo sapiens (human)1.637
P2Y purinoceptor 12Rattus norvegicus (Norway rat)0.04
Histone deacetylase 6Homo sapiens (human)1.14
Histone deacetylase 9Homo sapiens (human)1.637
Histone deacetylase 5Homo sapiens (human)1.637

Research

Studies (31)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (54.84)29.6817
2010's14 (45.16)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
Doak, AK; Prusiner, SB; Shoichet, BK; Wille, H1
Ekins, S; Williams, AJ; Xu, JJ1
Dalvie, D; Loi, CM; Smith, DA1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, LW; Chen, Z; Lu, XY; Wang, PF; Wang, ZC; Yan, XQ; Zhang, HW; Zhu, HL1
Chen, LW; Li, Z; Lu, XY; Lv, PC; Qiu, HY; Wang, PF; Wang, ZC; Yan, XQ; Zhu, HL1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Chen, LZ; Kong, FL; Lu, YD; Shen, FQ; Wang, MH; Wang, ZC; Yang, MR; You, LX; Zhu, HL1
Chen, Z; Grandis, JR; Li, M; Shin, DM; Wang, Z; Wieand, HS; Zhang, X1
Altundag, K; Altundag, O; Boruban, C; Silay, YS1
Dannenberg, AJ; Gibson, N; Lippman, SM; Subbaramaiah, K1
Chen, A; Chen, ZG; Choe, MS; Khuri, FR; Lin, Y; Shin, DM; Shin, HJ; Sun, SY; Wieand, HS; Zhang, X1
Haddad, RI; Joshi, VA; Lee, JC; Lindeman, NI; Norris, CM; Posner, MR; Wirth, LJ; Zhao, X1
Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H1
Cho, KH; Cho, MJ; Jun, HJ; Lee, JS; Park, JS; Pyo, H; Zo, JI1
Gadgeel, SM; Heath, EI; Heilbrun, LK; Ruckdeschel, JC; Venkatramanamoorthy, R; Wozniak, A1
Chen, Z; Choe, MS; Klass, CM; Shin, DM; Zhang, X1
Ahmed, F; Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A1
Chen, L; He, Y; Huang, H; Liao, H; Wei, W1
Agarwala, A; Breen, T; Bruetman, D; Einhorn, LH; Fisher, W; Hanna, N; Juliar, B; McClean, J; Taber, D; Titzer, M; Yu, M1
Baron, A; Basche, M; Dancey, J; Eckhardt, SG; Gore, L; Gustafson, DL; Holden, SN; Lam, ET; O'Bryant, CL; Serkova, N1
Ciou, SC; Hong, JH; Jhan, JY; Ko, JC; Lin, ST; Lin, YW; Wang, LH1
Bissonette, R; Brown, PH; Hill, J; Hilsenbeck, SG; Kittrell, F; Medina, D; Zhang, Y1
Abba, MC; Aldaz, CM; Bissonnette, RP; Brown, PH; Gaddis, S; Hill, J; Hu, Y; Kittrell, FS; Levy, CC; Medina, D1
Gong, P; Li, H; Li, J; Li, N; Ma, X; Su, F1
Hameed, I; Lin, JZ; Ren, ZY; Xu, Z; Yu, Y; Zhu, JG1
Chu, Q; Dai, H; Duan, Q; Fu, Y; Hu, H; Ji, X; Li, Y; Lin, X; Liu, L; Lu, H; Lu, S; Ma, T; Ni, X; Tian, Q; Wang, F; Xiao, J; Xiu, R; Xu, S; Xue, P; Yuan, P; Zeng, F; Zhang, J; Zhao, X; Zhu, F; Zou, L1

Reviews

1 review(s) available for gefitinib and celecoxib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

4 trial(s) available for gefitinib and celecoxib

ArticleYear
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-01, Volume: 23, Issue:28

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Pyrazoles; Quinazolines; Sulfonamides

2005
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Confidence Intervals; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Platinum; Probability; Pyrazoles; Quinazolines; Risk Assessment; Sulfonamides; Survival Analysis

2007
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Celecoxib; Disease-Free Survival; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrazoles; Quinazolines; Sulfonamides; Survival Rate

2008
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Celecoxib; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazoles; Quinazolines; Risk; Sulfonamides

2008

Other Studies

26 other study(ies) available for gefitinib and celecoxib

ArticleYear
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
    Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
Colloid formation by drugs in simulated intestinal fluid.
    Journal of medicinal chemistry, 2010, May-27, Volume: 53, Issue:10

    Topics: Buffers; Chemical Precipitation; Colloids; Intestine, Small; Light; Microscopy, Electron, Transmission; Pharmaceutical Preparations; Scattering, Radiation; Solubility

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Which metabolites circulate?
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5

    Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations

2013
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors.
    Bioorganic & medicinal chemistry letters, 2015, May-01, Volume: 25, Issue:9

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; Humans; MCF-7 Cells; Models, Molecular; Molecular Structure; Pyrazoles; Structure-Activity Relationship; Sulfonamides

2015
Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.
    Bioorganic & medicinal chemistry letters, 2015, Oct-15, Volume: 25, Issue:20

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Molecular Docking Simulation; Molecular Structure; Pyrazoles; Quantitative Structure-Activity Relationship; Sulfonamides

2015
Dihydropyrazothiazole derivatives as potential MMP-2/MMP-8 inhibitors for cancer therapy.
    Bioorganic & medicinal chemistry letters, 2018, 12-15, Volume: 28, Issue:23-24

    Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Drug Design; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 8; Matrix Metalloproteinase Inhibitors; Molecular Docking Simulation; Neoplasms; Pyrazoles; Quantitative Structure-Activity Relationship; Thiazoles

2018
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-01, Volume: 10, Issue:17

    Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Isoenzymes; Laryngeal Neoplasms; Lymphatic Metastasis; Membrane Proteins; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tyrphostins

2004
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2005, Volume: 49, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome

2005
Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides

2005
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; DNA-Binding Proteins; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Immunoblotting; Immunoenzyme Techniques; Membrane Proteins; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Prostaglandins E; Pyrazoles; Quinazolines; RNA, Small Interfering; STAT3 Transcription Factor; Sulfonamides; Trans-Activators; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A

2005
[Molecular-targeted therapy for hormone-refractory prostate cancer].
    Hinyokika kiyo. Acta urologica Japonica, 2006, Volume: 52, Issue:6

    Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D

2006
Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Aug-15, Volume: 12, Issue:16

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Cycle; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Rabbits; Radiation Tolerance; Sulfonamides

2006
Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, May-15, Volume: 13, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Docetaxel; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microtubules; Mitosis; Pyrazoles; Quinazolines; Sulfonamides; Taxoids

2007
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
    Cancer, 2007, Dec-15, Volume: 110, Issue:12

    Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Division; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Prostaglandins E; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured

2007
Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
    Medical oncology (Northwood, London, England), 2008, Volume: 25, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bisbenzimidazole; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides

2008
The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
    Lung cancer (Amsterdam, Netherlands), 2009, Volume: 65, Issue:3

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Gefitinib; Gene Expression Regulation; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Rad51 Recombinase; Sulfonamides

2009
Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.
    Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:2

    Topics: Animals; Anticarcinogenic Agents; Bexarotene; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Immunoenzyme Techniques; Incidence; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Pyrazoles; Quinazolines; Sulfonamides; Tetrahydronaphthalenes; Tumor Suppressor Protein p53

2009
Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.
    Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:2

    Topics: Animals; Anticarcinogenic Agents; Bexarotene; Biomarkers, Tumor; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Precancerous Conditions; Pyrazoles; Quinazolines; Sulfonamides; Tetrahydronaphthalenes; Tumor Protein, Translationally-Controlled 1; Tumor Suppressor Protein p53

2009
Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines

2015
Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
    Oncology reports, 2018, Volume: 40, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Docetaxel; Drug Resistance, Neoplasm; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Prostatic Neoplasms; Quinazolines; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2018
Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells.
    Cell death & disease, 2019, 10-14, Volume: 10, Issue:10

    Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mitogen-Activated Protein Kinase Kinases; Pantoprazole; Progression-Free Survival; Proto-Oncogene Proteins c-met; Signal Transduction; Xenograft Model Antitumor Assays

2019